Abstract
The cataleptic and antistereotypic abilities of clozapine, sulpiride and thioridazine were determined in the rat and compared with the responses of typical neuroleptic agents, haloperidol, fluphenazine and pimozide. Haloperidol and fluphenazine caused a dose-dependent cataleptic state which attained maximum intensity: the effects of pimozide were also dose-dependent but, although the catalepsy was marked, maximum intensity was not attained. In contrast, thioridazine, clozapine and sulpiride each caused a very weak, but definite, cataleptic response although a dose-dependency could not be demonstrated. Pretreatment of animals with α-methylparatyrosine was shown to significantly potentiate the cataleptic actions of haloperidol, fluphenazine, pimozide, thioridazine and sulpiride but failed to modify the action of clozapine. Threshold cataleptic doses of all agents markedly synergised in the production of catalepsy with threshold doses of the cholinergic drug RS86. Similarly, all “neuroleptic” agents tested were shown to reduce the intensity of the stereotyped behaviour induced by amphetamine, apomorphine and nomifensine in a dose-dependent manner but only haloperidol, fluphenazine and pimozide were shown to be capable of 100% inhibition. The antistereotypic abilities of haloperidol, fluphenazine and pimozide were most marked against amphetamine, but this was not a consistent observation for thioridazine, clozapine and sulpiride. Threshold, or even subthreshold, doses of both the typical and atypical neuroleptic agents combined with threshold doses of RS86 markedly synergised in the antagonism of the Stereotypic actions of amphetamine, apomorphine and nomifensine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andén, N.-E.: Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptic and anti-acetylcholine drugs. J. Pharm. Pharmacol. 24, 905–906 (1972)
Angst, J., Bente, D., Berner, P., Heimann, H., Helmchen, H., Hippius, H.: Das klinische Wirkungsbild von Clozapin. Pharmacopsychiat. 4, 201–214 (1971)
Baro, F., Van Lommel, R., Dom, R., De Mesmaecker, L.: Pimozide treatment of chronic schizophrenics as compared with haloperidol and penfluridol maintenance treatment. A multidisciplinary approach. Acta psychiat. belg. 72, 199–214 (1972)
Bartholini, G., Haefely, W., Jalfre, M., Keller, H. H., Pletscher, A.: Effects of clozapine on cerebral catecholaminergic neurone systems. Brit. J. Pharmacol. 46, 736–740 (1972)
Bobon, D. P., Plomteux, G., Heusghem, C., Bobon, J.: Clinical toxicology and efficacy of pimozide. Int. Pharmacopsychiat. 4, 194–203 (1970)
Borenstein, P., Champion, C., Cujo, Ph., Gekiers, P., Olivenstein, C., Kramarz, P.: An original psychotropic drug: sulpiride. Sem. HÔp. Paris 19, 1301–1314 (1969)
Burki, H. R., Ruch, W., Asper, H., Baggiolini, Stille, G.: Effect of single and repeated administration of clozapine on the metabolism of dopamine and noradrenaline in the brain of the rat. Europ. J. Pharmacol. 27, 180–190 (1974)
Caille, P.: Preliminary clinical experience with sulpiride. Nord. psykiat. T. 25, 340–346 (1971)
Costall, B., Naylor, R. J.: Neuroleptic and non-neuroleptic catalepsy. Arzneimittel-Forsch. 23, 674–683 (1973a)
Costall, B., Naylor, R. J.: Is there a relationship between the involvement of extrapyramidal and mesolimbic brain areas with the cataleptic action of neuroleptic agents and their clinical antipsychotic effect? Psychopharmacologia (Berl.) 32, 161–170 (1973b)
Costall, B., Naylor, R. J.: Stereotyped and circling behaviour induced by dopaminergic agonists after lesions of the midbrain raphé nuclei. Europ. J. Pharmacol. 29, 206–222 (1974a)
Costall, B., Naylor, R. J.: Mesolimbic involvement with behavioural effects indicating antipsychotic activity. Europ. J. Pharmacol. 27, 46–58 (1974b)
Costall, B., Kelly, D. M., Naylor, R. J.: Nomifensine: A potent dopaminergic agonist of antiparkinson potential. Psychopharmacologia (Berl.) (in press 1975)
De Maio, D.: Preliminary clinical evaluation of a new neuroleptic agent: HF 1854 in: The present status of psychotropic drugs, A. Cerletti and F. J. Bové, eds., pp. 485–488. Amsterdam: Excerpta Medica Foundation 1969
Dorris, R. L., Shore, P. A.: Actions of clozapine on the dopamine neuron. Fed. Proc. 33, 511 (1974)
Goldman, D.: Parkinsonism and related phenomena from administration of drugs: their production and control under clinical conditions and possible relation to therapeutic effect. In: Extrapyramidal system and neuroleptics. J.-M. Bordeleau, ed., pp. 453–464. Editions psychiatriques, Montreal 1961
Haase, H. J., Floru, L., Ulrich, F.: Clinical neuroleptic investigation of N-[(1-ethyl-pyrrolidine-2-yl)-methyl]-2-methoxy-5-sulfamoyl benzamide the neuroleptic sulpiride (Dogmatil) using acute schizophrenics. Int. Pharmacopsychiat. 9, 77–94 (1974)
Hornykiewicz, O.: Parkinsons disease: from brain homogenate to treatment. Fed. Proc. 32, 183–190 (1973)
Janssen, P. A. J., Niemegeers, J. E., Schellekens, K. H. L., Lenaerts, F. M.: Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data. Arzneimittel-Forsch. 17, 841–854 (1967)
Laville, Cl., Margarit, J.: Influence of sulpiride on motor activity and vigilance in the mouse. Path. et Biol. 16, 663–665 (1968)
Loew, D. M.: The prediction of sedative potency of neuroleptics. In: Modern problems of pharmacopsychiatry, vol. 5, D. P. Bobon, P. A. J. Janssen, and J. Bobon, eds., pp. 47–50. Basel: Karger 1970
Miller, R. J., Hiley, C. R.: Anti-muscarinic properties of neuroleptics and drug induced Parkinsonism. Nature (Lond.) 248, 596–597 (1974)
Miller, R. J., Horn, A. S., Iversen, L. L.: The action of neuroleptic drugs on dopamine-stimulated adenosine cyclic 3′,5′-monophosphate productions in rat neostriatum and limbic forebrain. Molec. Pharmacol. 10, 759–766 (1974)
Muller, P., Seeman, P.: Neuroleptics: relation between cataleptic and anti-turning actions, and role of the cholinergic system. J. Pharm. Pharmacol. 26, 981–984 (1974)
Sayers, A. C., Kleinlogel, H.: Neuropharmakologische Befunde unter chronischer Verabreichung von Haloperidol, Loxapine und Clozapin. Arzneimittel-Forsch. 24, 981–982 (1974)
Snyder, S., Greenberg, D., Yamamura, H. I.: Antischizophrenic drugs and brain cholinergic receptors. Arch. gen. Psychiat. 31, 58–61 (1974)
Stille, G., Lauener, H., Eichenberger, E.: The pharmacology of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo (b,e) (1,4) diazepine (clozapine). Farmaco, Ed. Sci. 26, 603–625 (1971)
Vinar, O., Kršiak, M.: Prediction of Neuroleptic effects from animal data. In: Phenothiazines and structurally related drugs, I. S. Forrest, C. J. Carr, and E. Usdin, eds., pp. 675–683. New York: Raven Press 1974
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Costall, B., Naylor, R.J. Detection of the neuroleptic properties of clozapine, sulpiride and thioridazine. Psychopharmacologia 43, 69–74 (1975). https://doi.org/10.1007/BF00437617
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00437617